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Abstract 
 
Lung cancer is the leading cause of cancer death in both men and women in the United 
States. Nevada shows moderate incidence rates of lung cancer for men but high rates for women. 
Little is known about the lung cancer experience and survival characteristics of the nearly 2000 
new cases occurring every year in the State. The purpose of this study was to measure the extent 
to which geographic area of residency, gender, race, health insurance, social economic status 
(SES) and stage at diagnosis were associated with survival in patients diagnosed with lung cancer 
in Nevada. This was a retrospective population-based cohort study utilizing the Nevada Central 
Cancer Registry (NCCR) database for incident cases of lung cancer diagnosed in the state from 
2003-2010 and followed-up through December 2011. The study population included all patients 
with incident cases of invasive carcinoma of the lung and bronchus, site codes C34.0, C34.3, 
C34.8, C34.9 and morphology codes 8000–8576. Five year cumulative survival rates were 
computed using the life table method stratified by race and adjusted for age. Cox proportional 
hazards regression was performed adjusting for region, age, gender, SES, race, tumor stage, 
marital status, histology, and insurance types, to examine the influence of each of these 
determinants on lung cancer survival in Nevada. A total of 12,962 lung cancer cases were 
diagnosed in Nevada during 2003-2010. The fatality of this cancer was very high with 81.9 % of 
the cases deceased by the end of the follow-up period. The overall age-standardized 5 year 
survival rate for Nevada lung cancer patients was 16.44% (95%CI 15.74-17.14). Blacks had a 
lower combined, age adjusted 5 year survival rate of 13.63% (95% CI 10.24-16.48) compared to 
the rate of Whites, 16.55 % (95% CI 15.8-17.30). However, after adjustment for all confounders, 
Blacks did not show an increased risk of death compared to Whites, (HR 0.99, 95% CI 0.904-
1.077). 
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 Asians (HR 0.80, 95% CI 0.71-0.89) and Hispanics (HR 0.84, 95% CI 0.76-0.93) exhibited 
better lung cancer survival over time compared to Whites. Patients from Southern and Rural 
Nevada had an 8.5 % (p=0.001) and 11.3 % (p=0.008) higher risk of dying respectively, 
compared to patients from Northwestern Nevada. This study provides much needed baseline lung 
cancer survival data for Nevada. There was no lung cancer survival disparity between Blacks and 
Whites. The apparently better survival rates of Asians and Hispanics should be interpreted with 
caution as it may be due to death linkage artifacts. Disparities between different parts of the state 
warrants further study.  
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Chapter 1 
Background and Significance 
Introduction 
Lung cancer is the leading cause of cancer deaths in both men and women in the United 
States. In year 2010, a total of 201,144 people in the United States were diagnosed with lung 
cancer, including 107,164 men and 93,980 women. In the same year 158,248 people in the United 
States died from lung cancer, including 87,698 men and 70,550 women (CDC WorkingGroup., 
2011). Nationally, lung cancer survival rates continue to be very low (Siegel, Naishadham, & 
Jemal, 2013). Nevada has a significantly higher rate of lung cancer incidence and  mortality  
compared to the rest of the Western US (Siegel et al., 2013).  Pinheiro , Reid , Saccucci  and 
Harris  (2012) found that 1,310 deaths occurs every year from lung cancer in Nevada, more than 
breast cancer, colorectal cancer and prostate cancer combined. 
Risk factors. A number of environmental and life-style factors have been associated with the 
subsequent development of lung cancer, of which cigarette smoking is the most important 
(Alberg & Samet, 2003). Other risk factors includes exposure to second-hand smoke, radon, 
arsenic, asbestos, radiation therapy to the breast or chest polycyclic aromatic hydrocarbons, other 
agents, and air pollution (Wingo et al., 1999). 
Clinical features. Lung cancer symptoms and signs may result from the location of the 
primary local invasion, compression of adjacent chest wall structures, distant metastases, or by 
hormone like features. The most common symptoms at presentation are worsening cough or chest 
pain. 
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Screening. Screening for lung cancer has not been widely implemented. Previous studies of 
lung cancer screening with chest radiography and sputum cytology failed to demonstrate  lower 
lung cancer mortality rates (Finigan & Kern, 2013). The only screening modality for early 
detection that has been shown to alter mortality, is low-dose helical CT scanning among high-risk 
patients such as heavy smokers (Aberle et al., 2011). 
Histology types. According to the website of the National Cancer Institute  (NCI, 2014), lung 
carcinomas are broadly classified into Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell 
Lung Carcinoma (SCLC). NSCLC is a heterogeneous aggregate of histologies. The most 
common NSCLC histologies include squamous cell carcinoma (SCC), adenocarcinoma (ADK) 
and large cell carcinoma. These histologies are often classified together because of similar 
approaches to diagnosis, staging, prognosis, and treatment. 
Treatment. In NSCLC, surgery offers the greatest chance of cure in appropriate cases, but 
results of standard treatment are poor except for the most localized cancers (Manser, Wright, 
Hart, Byrnes, & Campbell, 2005). SCLC is more responsive to chemotherapy and radiation 
therapy than other cell types of lung cancer; however, a cure is difficult to achieve because SCLC 
has a greater tendency to be widely disseminated at the time of diagnosis (Fry, Menck, & 
Winchester, 1996; Govindan et al., 2006; Jänne et al., 2002). 
Survival. The stage at presentation in patients with NSCLC is the factor that has the greatest 
impact on prognosis (Harpole, Herndon, Young, Wolfe, & Sabiston, 1995; Pairolero et al., 1984). 
The most important prognostic factor in patients with SCLC is the extent of disease (stage) at 
presentation. For patients with limited stage disease, median survival range from 15 to 20 months 
and the reported five-year survival rate is 10 to 13%. In contrast, for patients with extended stage 
disease, the median survival is 8 to 13 months, and the five-year survival rate is extremely low at 
1 to 2 %  (Johnson et al., 1990). 
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Disparities 
Like other major cancers, the disease burden of lung cancer is not shared equally in the 
US population. Minorities often have an increased incidence rate and a decreased overall survival 
rate (Siegel et al., 2013). Poor outcome in survival has been attributed to multiple reasons 
including age, gender, histological type, performance status, stage, socioeconomic status, and 
health disparities (Forrest, Adams, Wareham, Rubin, & White, 2013; Grivaux et al., 2011; 
Mulligan et al., 2006; Niu, Roche, Pawlish, & Henry, 2013).  
Despite improving cancer mortality, health disparities in cancer survival including lung 
cancer continue to exist (Cheung et al., 2009; CDC working group., 2011; Pinheiro  et al., 2012; 
Zheng et al., 2012). In a systematic review by Forrest et al., (2013), patients with lung cancer 
living in more socioeconomically deprived circumstances are less likely to receive any type of 
treatment, surgery, and chemotherapy. In the United States, uninsured and Medicaid insured 
patients with lung cancer have higher mortality or lower survival than patients with private 
insurance or Medicare, even after adjustment for other factors (Niu et al., 2013). Some studies 
have demonstrated that providing equal access to health care may eliminate racial disparities in 
lung cancer survival and improve the outcome of all cases (Zheng et al., 2012). 
Cancer incidence and survival disparities have been reported in Nevada (Pinheiro et al.,  
2012). The report suggests existence of regional disparities in survival rates in Nevada for breast, 
colon, prostate, cervical, and skin (melanoma) cancers, possibly due to less accessibility to 
quality healthcare in Southern Nevada. However, lung cancer survival disparities in Nevada were 
not analyzed, although the study reported that in Nevada, only 16% of the cancers were detected 
in a localized stage, 19% in regional stage and 42% in distant stage, with 23% having an 
unknown stage of diagnosis.  
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Given the high burden of morbidity and mortality associated with lung cancer and the 
lack of baseline data available to researchers, administrators and policy makers in the state of 
Nevada, the purpose of this thesis is to study lung cancer survival disparities and their 
determinants. Accurate estimation of lung cancer survival and its associated factors will better 
facilitate public health policies for allocating resources to people at highest risk which in turn will 
improve quality healthcare delivery and disease prevention. 
Study Purpose and Hypotheses 
Research questions. Given that lung cancer has a very poor prognosis in the population at 
large, the study sought to answer the following questions: do lung cancer survival disparities exist 
in Nevada, how large they are and what are the determinants associated with such disparities.  
Goal and objectives. The purpose of this study was to measure the extent to which 
geographic residency, gender, race, health insurance, SES and stage at diagnosis are associated 
with survival over time in patients from Nevada diagnosed with lung cancer.  
Hypotheses. To answer the research questions the following hypotheses will be tested:  
H1: Lung cancer patients in Northwestern Nevada show lower risk of death for lung cancer 
over time compared to those in Southern Nevada.  
Ho: There is no difference in risk of death from lung cancer over time between Southern and 
Northwestern Nevada. 
H2: In Nevada, Blacks presenting with distant stage lung cancer are less likely to receive 
chemotherapy than Whites.  
Ho: In Nevada, there is no difference in treatment with chemotherapy between Blacks and 
Whites with distant lung cancer. 
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H3: In Nevada, lung cancer patients from low economic status exhibit higher risk of death 
overtime compared to higher SES. 
Ho: In Nevada, there is no difference in risk of death over time between lung cancer patients 
from lower and higher socioeconomic status. 
H4: Patients from Rural Nevada with localized NSCLC lung cancer are less likely to receive 
surgery compared to those in Southern and Northwestern Nevada. 
Ho: There is no difference in surgical treatment between Patients with localized NSCLC from 
Rural Nevada compared to Southern and Northwestern Nevada. 
H5: Overall, Nevada patients with SCLC have increased risk of death compared to those with 
SCC. 
Ho: Overall, there is no difference in survival in Nevada, between patients with SCLC and 
SCC. 
Ethical considerations. The study was approved by the University of Nevada, Las Vegas 
IRB; Protocol # 1403-4762M. 
  
 6 
 
Chapter 2 
Methodology 
Study Design 
Data source. Lung cancer data were obtained from the Nevada Central Cancer Registry 
(NCCR) through the Bureau of Health Planning and Statistics. The NCCR is a population-based 
registry that records and maintains data on all cancer patients within the State of Nevada. The 
Nevada statewide cancer registry achieved seven gold certifications with the North American 
Association of Central Cancer Registries in the last ten years. The details of NCCR case finding 
methodology and operations are described on its website (Nevada Division of Public and 
Behavioral Health, 2011). Death records came from the Office of Vital Records (OVR), also 
within the Bureau of Health Planning and Statistics. Out of state deaths were captured by manual 
search through the Social Security Death Index of all cases initially given out by the Registry as 
being alive (Boyle & Decouflé, 1990; Hill & Rosenwaike, 2001/2002).  Comparison survival 
rates were obtained from Surveillance, Epidemiology, and End Results (SEER) Program. The 
SEER Program is a population-based cancer registration program coordinated by the NCI which 
identifies all primary cancers occurring in residents of defined geographic regions. Cancer 
registries of the SEER Program currently cover approximately 26% of the U.S. population. SEER 
collects detailed data on patient demographics, tumor characteristics, and initial therapy, and 
maintains follow-up of all registered patients for vital status in order to provide statistics on 
cancer patient survival (SEER Cancer Statistics Review 1975-2004 , 2007). 
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Study population. The study population in this study comprised men and women diagnosed 
with a first primary lung and bronchial cancer 2003 through 2010 identified through the NCCR 
and followed for vital status until December, 31 2011. The site codes included were C34.0–34.3, 
C34.8–34.9 while morphology codes included were 8000–8576  as described by Fritz et al., 
(2000) in International Classification of Diseases for Oncology, third edition (ICD-O-3). The 
Study went on with 12,962 cases out of the possible 13,653 cases that met the inclusion criteria. 
Exclusion criteria. Patients only diagnosed at autopsy and by death certificate were excluded 
(687 cases). Also, patients with negative or missing survival period were also excluded (3 cases). 
Outcome measure. The primary endpoint was observed survival. Survival time was 
measured in years from the date of diagnosis until the date of death, or the end of the study 
(December 31, 2011), whichever occurred first. 
Variables 
Lung cancer stage of diagnosis classification. SEER Program  summary staging (localized, 
regional, and distant) was used to categorize the extent of the disease  (Young  Jr, Roffers , Ries 
& Fritz , 2001).   
Age categorization. Age at diagnosis was categorized into the following 5 groups: 15-44, 45-
54, 55-64, 65-74, 75+ based on the international age standard survival classification (Fritz A et 
al., 2000). 
Lung cancer histology classification. Lung cancer was classified into 5 categories: Non 
Specific Lung Cancers/ Neoplasm (8000/3-8005/3,8010/3-8015/3 ,8020/3,8021/3), 
SCLC(8041/3-8045/3,8246/3), SCC  (8050/3-8052/3, 8070/3-8076/3, 8078/3), ADK( 8140/3, 
8141/3, 8143/3, 8147/3, 8250/3- 8255/3,8260/3, 8310/3, 8320/3, 8323/3, 8480/3, 8481/3, 8490/3, 
8510/3, 8550/3, 8551/3, 8570/3- 8574/3, 8576) and Others ( all other codes not listed above). 
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Race/ Ethnicity. Race/ ethnicity was classified into the following mutually exclusive groups: 
White, Black, Hispanic, Asian/Pacific Islanders, Native Americans and Others. 
Poverty level. SES information is not directly collected on individual patients by NCCR. SES 
was based on proportion of the population in poverty in the case’s zip code based on 2011 US 
Census Bureau data (American Community Survey, 2011). The three categories of ecological 
SES considered were high SES (< 5 percent of population in poverty), middle SES (5-10 percent 
of population in poverty) and low SES (>10 percent of population in poverty). 
Nevada geographical region classification. Nevada was classified into Southern, 
Northwestern and Rural regions. Clark County was referred to as Southern Nevada. Northwestern 
Nevada comprised of Douglas, Lyon, Storey, Washoe Counties and Carson City. The remainders 
of the counties (Humboldt, Pershing, Lander, Elko, Eureka, White Pine, Nye, Lincoln, 
Esmeralda, Mineral and Churchill) were classified as Rural Nevada.    
Marital status. Marital status were classified according to the North American Association of 
Central Cancer Registries standards (The Florida Cancer Data System - Data Acquisition Manual, 
2013). For analysis purpose, patients were described as single, married, widowed or 
divorced/separated.   
Health insurance. Insurance types were classified  according to the North American 
Association of Central Cancer Registries standards (The Florida Cancer Data System - Data 
Acquisition Manual, 2013.). For analysis purpose Insurance status were reclassified into 
uninsured, private and Medicaid. Veteran affairs (VA) and Medicare were included as part of 
private insurance. The Indian health insurance was grouped with Medicaid.  
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Statistical Analyses 
All data were analyzed with SPSS (version 22, SPSS Inc., and Chicago, IL, USA). 
Statistical analyses were carried out using likelihood ratio chi-square tests to compare the 
demographics, tumor histology, stage and accessibility to healthcare for race and ethnicity 
groups. The cumulative 5-year survival rates/curves were computed by the life table method 
stratified by race and adjusted for age. Survival rates were calculated using the actuarial method. 
Univariate and multivariate Cox proportional hazards regression was performed using all 
variables of interest. Hazard ratios were computed adjusting for region, age, gender, SES, race, 
tumor stage, marital status, histology, and insurance status.  
Cross tabulation tables were carried out to test the appropriate hypotheses. To further test some 
hypothesis in a multivariate way, logistic regression was done, adjusting for appropriate 
variables. Partial likelihood tests were used to estimate the regression coefficients. All statistical 
tests were two-sided with p-value of <0.05 reported as statistically significant. 
Cox Models. A Cox model is a statistical technique for exploring the relationship 
between the survival of a patient and several explanatory variables. It allows the estimation of the 
hazard (or risk) of death or other event of interest. It assumes that the effects of the explanatory 
variables upon survival are constant over time and are additive in one scale. This is known as 
proportional hazard assumption. The hazard function is the probability that an individual or object  
will experience an event  ( such as death) within  time interval, given that the individual has 
survived up to the beginning of the interval.(“ XLSTAT,” 2014).  
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Chapter 3 
Results 
Descriptive Analysis 
A total of 12,962 diagnoses of lung cancer from 2003 through 2010 were included in the 
study. Of those diagnoses, 51.4 % [n=6656] were male and the remaining 48.6 % [n=6306] were 
female. Whites made up the largest proportion of the patients in Nevada, constituting 86.4 % 
[n=11193]. Other racial-ethnic groups included Blacks 5.2 % [n=680], Native Americans 0.5 % 
[n=67], Asian 3.3 % [n=423], and Hispanics 4.4 % [n=567]. A very small proportion of the 
population were unknown race or multiracial 0.2 % [n=32]. 
For the period 2003 through 2010, the mean age of Nevada patients diagnosed with lung 
cancer was 68.9 years with a standard deviation of 10.3. The most common (36 %) age group for 
lung cancer diagnosis was 65-74 years [n=4665]. Most of the lung cancers were unstaged (35.6 
%). Distant or metastatic stage was 31.0 %. Only 17.5 % were diagnosed at localized stage. The 
remaining 15.9 % were diagnosed at a regional stage. Most of the patients, 73.9 %, had private 
health insurance or Medicare. A small proportion or2.9 % was covered with Medicaid. Uninsured 
patients constituted 3.4 % of the cases. The remaining 19.8 % had unknown health insurance at 
the time of their diagnosis. In terms of diagnosed histology, ADK was the largest proportion (33.1 
%). SCC was diagnosed in 16.6 % of population studied. The rest were distributed as follows: 
SCLC (14.8 %), carcinomas NOS (14.3 %) and others (21.1 %). Predominantly, 69 % of the lung 
cancer patients resided in Southern Nevada. Rural Nevada contributed 7.8 % of the cases. 
Northwestern Nevada recorded 23.2 % of the cases.  48.4 %, of the Nevada lung cancer patients 
were married. The lower SES constituted a large proportion of the cases (45.2 %). Please see 
table 1 for the detailed demographic and clinical characteristics of the study population. 
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Table 1
Patients' Dermographic and Clinical Characteristics by Race/Ethnicity ( N=12962)
Race White Black N.A Asian/PFI Hispanics Unknown Total p value*
n=11193 n=680 n=67 n=423 n=567 n=32 N=12962
Age at diagnosis <0.001
<45 129 22 1 10 21 2 185
45-54 745 95 8 50 74 2 974
55-64 2561 192 13 114 145 7 3032
65-74 4084 222 24 153 168 14 4665
75+ 3674 149 21 96 159 7 4106
Sex <0.001
Male 5659 372 48 236 323 18 6656
Female 5534 308 19 187 244 14 6306
Stage at diagnosis 0.001
Localized 2005 104 15 60 75 6 2265
Regional 1786 115 10 68 79 6 2064
Distant 3405 236 31 143 194 12 4021
Unstaged 3997 225 11 152 219 8 4612
Marital status <0.001
Married 5447 264 32 266 247 17 6273
Single 1531 180 9 52 105 3 1880
Separated/Divorced 1363 95 9 33 67 6 1573
Widowed 2070 97 11 49 61 6 2294
Unknown 782 44 6 23 87 0 942
Insurance <0.001
Private/Medicare 8318 501 48 324 356 29 9576
Medicaid 279 36 6 15 36 2 374
Uninsured 318 44 3 28 48 0 441
Unknown 2278 99 10 56 127 1 2571
Nevada Region <0.001
Northwestern 2794 37 28 53 82 7 3001
Rural 956 9 13 4 33 0 1015
Southern 7443 634 26 366 452 25 8946
Histology <0.001
SCC 1861 128 11 64 86 7 2157
SCLC 1713 75 7 42 81 3 1921
ADK 3594 264 22 202 197 13 4292
Carcinoma NOS 1644 63 14 45 81 5 1852
Others 2381 150 13 70 122 4 2740
Proportion in poverty <0.001
<5 percent 2100 70 6 90 65 10 2341
5-10 percent 3990 211 15 187 150 10 4563
>10 percent 4923 390 44 143 346 12 5858
Unknown 180 9 2 3 6 0 200
Notes: Abbreviations: N.A, Native Americans; PFI, Pacific Islanders; SCC, Squamous Cell Carcinomacarcinoma
 ADK, Adenocarcinoma; NOS, Not otherwise Specified; SCLC, Small Cell Lung Cancer;SCL ,Small Cell Lung Cancer
*Likelihood ratio p value, significant at p<0.05.
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There were 10619 (81.9 %) deaths in Nevada lung cancer patients by the end of the 
follow up period (2003 – 2011). Demographically, Blacks, Native Americans, Asians, and 
Hispanics tended to be diagnosed at a younger age (before 55 years) with proportions of 17.2 %, 
13.4 %, 14.2 % and 16.8 % respectively versus 7.8 % of Whites. Hispanics had higher proportion 
of uninsured patients than other races/ethnicity at 8.5 % compared to Whites (2.5 %), Blacks (6.5 
%), Native Americans (4.5 %) and Asians (6.6 %). At the time of diagnosis of lung cancer, lower 
proportion of Asians (33.8 %) had a   low economic status compared to Whites (44 %), Blacks 
(57.4 %), Native Americans (65.7 %) and Hispanics (61 %). A higher proportion of Native 
Americans (48.4 %) were diagnosed at distant stage of lung cancer compared with other races as 
follows: Whites (30.4 %), Blacks (34.7 %), Asians (33.8 %) and Hispanics (34.2 %) respectively. 
Higher proportion of Whites were diagnosed with the more aggressive SCLC (15.3 %) compared 
to other races/ethnicities. Small cell histology was diagnosed in 11 % of Blacks, 10.5 % of Native 
Americans, 9.9 % of Asians and 14.2 % of Hispanics. 
Survival Analyses 
Lung cancer survival rates. In this particular study, it was found that the median overall 
survival for the entire cohort was 1.04 years. Age-adjusted survival rates were obtained using the 
international survival standards (Corazziari, Quinn, & Capocaccia, 2004) and compared with the 
general population derived from Surveillance Epidemiology and End Results (SEER) -17. The 
overall age-standardized observed 5 year survival rate for Nevada lung cancer patients was 16.44 
% (95% CI 15.74-17.14). This was not statistically different from SEER overall lung cancer 
survival rate of 16.40 % (95% CI 16.20-16.50) (Table 2). When stratified by gender (Table 3), 
Nevada females had a significantly higher 5 year survival rate (19.65%, 95% CI 18.56-20.74) 
versus Nevada males (12.96%, 95% CI 12.07-13.85). This is similar to the SEER national 
findings. In addition, when Nevada males and females were compared with SEER males 
(13.60%, 95%CI 13.4-13.70) and females (19.60%, 95% CI 16.2-16.5), there were no difference 
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between Nevada and the rest of the nation (Tables 3& 4). 
 
 
 
 
 
Table 2
Race Survival (%) LLCI ULCI Survival (%) LLCI ULCI
Whites 16.6 16.4 16.8 16.55 15.8 17.3
Blacks 12.5 12.2 12.9 13.63 10.24 16.48
N.A 11.7 9.9 13.6 6.38 0.15 12.61
A/PFI 19.9 19.2 20.5 17.27 12.98 21.56
Hispanics 17.9 17.3 18.5 17.64 14.11 21.17
Overall 16.4 16.2 16.5 16.44 15.74 17.14
Notes  : Abbreviations: NA, Native Americans, A/PFI, Asians/Pacific Islanders;
LLCI, Lower Limit of 95% Confidence Interval; ULCI, Upper Limit of 95% Confidence Interval
SEER, Surveillance Epidemiology and End Results
SEER Nevada
Lung Cancer Age Standardized 5 Year Survival Rates  for SEER  and Nevada
Table 3
Race Survival (%) LLCI ULCI Survival (%) LLCI ULCI
Whites 13.1 12.14 14.06 19.67 18.52 20.82
Blacks* 8.02 4.41 11.63 19.47 14.29 24.65
N.A* 2.03 0.01 8.11 19.72 1.48 37.96
A/PFI 14.81 9.64 19.98 19.44 12.16 26.72
Hispanics 14.85 10.44 19.26 22.09 16.33 27.85
Overall* 12.96 12.07 13.85 19.65 18.56 20.74
Notes : Abbreviations: NA, Native Americans, A/PFI, Asians/Pacific Islanders;
LLCI, Lower Limit of 95% Confidence Interval; ULCI, Upper Limit of 95% Confidence Interval
* Significant compare to Whites
Male Female
Nevada  Age Standardized  5 year Survival Rates of Lung Cancer  by Gender
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When survival rates were broken down further by race/ethnicity and gender, Nevada females had 
consistently higher survival rates than their male counterparts (Table 3). These differences in 
male and female survival rates are comparable to the patterns seen in patients residing in the 
SEER regions (Table 4). Only Native Americans had a significantly lower overall survival rate 
(6.38 %, 95% CI 0.15-12.61) compared to Whites (16.55%, 95% CI 15.8-17.30).  Blacks had 
lower but non-significant overall adjusted 5-year survival rate (13.63%, 95%CI 10.24-16.48) 
compared to Whites (16.55%, 95% CI 15.8-17.30). Once stratified by gender, Nevada Black 
males (8.02%, 95% CI 4.41- 11.63) and Native Americans (2.03%, 95% CI 0.01-8.11) exhibited a 
lower 5-year survival rate compared to White males (13.1%, 95% CI 12.14-14.06). There were no 
racial survival differences amongst Nevada females (Table 3).  
  
Table 4
Race Survival (%) LLCI ULCI Survival (%) LLCI ULCI
Whites 13.7 13.5 13.9 19.9 19.6 20.1
Blacks 10.6 10.1 11 15.2 14.6 15.8
N.A 10 7.7 12.6 13.3 10.7 16.2
A/PFI 16.6 15.8 17.5 24.3 23.2 25.4
Hispanics 14.9 14.2 15.7 21.4 20.4 22.4
Overall 13.6 13.4 13.7 19.6 19.4 19.9
Notes : Abbreviations: NA, Native Americans, A/PFI, Asians/Pacific Islanders;
LLCI, Lower Limit of 95% Confidence Interval; ULCI, Upper Limit of 95% Confidence Interval
SEER  Age Standardized  5 year Survival Rates of Lung Cancer  by Gender
Male Female
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Cox regression model 
Proportional hazard assumption test. The proportional hazard assumption was tested for all 
the variables. All variables except radiotherapy and chemotherapy satisfied this assumption. 
Although surgery as a treatment modality satisfied the proportional hazard test it was excluded 
from the main model, alongside chemotherapy and radiotherapy, because it is only appropriate 
for early NSCLC. Univariate model was first performed to assess the impact of each variable 
alone on lung cancer survival.  Multivariable model was performed next, to account for other 
covariates. In the multivariate model, adjusted hazard ratios (HR) and the corresponding 95 % 
confidence intervals (CI) were estimated using the Cox proportional hazards regression. The 
forward stepwise method was employed. Univariate analysis of all the variables of interest 
demonstrated significant contribution to lung cancer survival (Table 5). In the multivariate 
models, all variables of interest remained significant after simultaneously adjusting for other 
variables (Table 5). 
Effect of race/ethnicity on survival. Race has been shown to be a determinant of cancer 
survivals. In our study, there was no difference between Blacks (HR 0.99, 95% CI 0.91-1.08, 
p=0.91) and Whites (reference) unadjusted for other factors. The lack of difference between 
Blacks and Whites remained in the multivariate model (Table 5) when simultaneously adjusted 
for age group, gender, stage, health insurance type, marital status, SES, tumor histology and 
geographical regions. Blacks had a HR 0.99, 95% CI 0.90-1.08, p=0.762; compared to Whites 
(the reference group). Surprisingly, this study result suggests that Asian (adjusted HR 0.80, 95% 
CI 0.71-0.89, p<0.001) and Hispanic (adjusted HR 0.84, 95% CI 0.76-0.93, p<0.001) lung cancer 
patients had lower risk of death compared to Whites whether adjusted or unadjusted for other 
confounders (Table 5 & Figure 1).   
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Effect of geographical region on survival. There was no difference in crude survival 
between Northwestern Nevada (reference group) and Southern Nevada (HR 1.01, 95% CI 0.97-
1.06, p =0.63). However, In the multivariate model, after simultaneously adjusting for age group, 
gender, stage, health insurance type, marital status, SES, tumor histology and race/ethnicity, 
Southern Nevada lung cancer patients had a 9 % higher risk of dying compared to Northwestern 
Nevada ( HR 1.09,95% CI 1.04-1.14, p =0.001). Rural Nevada patients, on the other hand, had 
significantly increased risk of death unadjusted and adjusted for confounders compared to 
Northwestern Nevada (Table 5). 
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Table 5
Type
HR LLCI  ULCI P value* HR LLCI ULCI P value*
Sex <0.001 <0.001
Male 1.00 1.00
Female 0.81 0.78 0.84 <0.001 0.81 0.78 0.85 <0.001
Age at diagnosis <0.001 <0.001
<45 1.00 1.00
45-54 1.60 1.31 1.95 <0.001 1.59 1.31 1.94 <0.001
55-64 1.62 1.35 1.96 <0.001 1.75 1.45 2.11 <0.001
65-74 1.75 1.45 2.11 <0.001 2.04 1.69 2.46 <0.001
75+ 2.26 1.87 2.72 <0.001 2.63 2.17 3.18 <0.001
Race/Ethnicity <0.001 <0.001
White 1.00 1.00
Black 0.99 0.91 1.08 0.91 0.99 0.90 1.08 0.762
N.A 1.47 1.14 1.89 0.003 1.38 1.07 1.78 0.012
Asian/PFI 0.79 0.71 0.88 <0.001 0.80 0.71 0.89 <0.001
Hispanics 0.92 0.84 1.01 0.09 0.84 0.76 0.93 <0.001
Unknown 0.77 0.51 1.18 0.23 0.88 0.58 1.34 0.564
Stage at diagnosis <0.001 <0.001
Localized 1.00 1.00
Regional 1.62 1.51 1.74 <0.001 1.63 1.51 1.75 <0.001
Distant 3.65 3.43 3.89 <0.001 3.65 3.42 3.89 <0.001
Unstaged 2.35 2.21 2.50 <0.001 2.13 1.99 2.27 <0.001
Marital status <0.001 <0.001
Married 1.00 1.00
Single 1.23 1.16 1.30 <0.001 1.20 1.13 1.27 <0.001
Separated/Divorced 1.13 1.07 1.21 <0.001 1.11 1.04 1.18 0.001
Widowed 1.23 1.17 1.30 <0.001 1.11 1.05 1.17 <0.001
Unknown 0.96 0.89 1.04 0.33 0.81 0.75 0.88 <0.001
Insurance <0.001 <0.001
Private/Medicare 1.00 1.00
Medicaid 1.18 1.05 1.32 0.004 1.13 1.01 1.28 0.036
Uninsured 1.36 1.22 1.51 <0.001 1.20 1.08 1.34 0.001
Unknown 1.45 1.38 1.52 <0.001 1.32 1.25 1.39 <0.001
Nevada Region 0.003 0.002
Northwestern 1.00 1.00
Rural 1.14 1.05 1.23 0.001 1.11 1.03 1.20 0.008
Southern 1.01 0.97 1.06 0.63 1.09 1.04 1.14 0.001
Histology <0.001 <0.001
SCC 1.00 1.00
SCLC 1.53 1.43 1.64 <0.001 1.28 1.20 1.37 <0.001
ADK 0.94 0.89 1.00 0.06 0.91 0.86 0.97 0.003
Carcinoma NOS 2.15 2.01 2.30 <0.001 1.68 1.57 1.81 <0.001
Others 1.23 1.15 1.31 <0.001 1.09 1.02 1.16 0.008
Proportion in poverty <0.001 <0.001
<5 percent 1.00 1.00
5-10 percent 1.17 1.11 1.24 <0.001 1.15 1.09 1.22 <0.001
>10 percent 1.28 1.22 1.36 <0.001 1.22 1.16 1.29 <0.001
Unknown 1.24 1.06 1.45 0.01 1.10 0.94 1.28 0.257
Notes: Abbreviations: N.A, Native Americans; PFI, Pacific Islanders; SCC, Squamous Cell Carcinoma
 ADK, Adenocarcinoma; NOS, Not otherwise Specified; SCLC, Small Cell Lung Cancer; HR; Hazard Ratio;
 LLCI, Lower Limit  of 95%  Confidence Interval of HR; ULCI, Upper  Limit  of 95%  Confidence Interval of HR ;
* p value, significant at p<0.05.
Univariate (N=12962) Multivariate (N=12962)
Cox Regression Model
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Effect of gender on survival. Both univariate and multivariate analyses showed that female 
gender was advantageous. When simultaneously adjusted for age group, race, stage, health 
insurance type, marital status, SES, tumor histology and geographical regions, females were 19 % 
less likely (HR 0.81, 95% CI 0.78-0.85, p<0.001) to die from lung cancer over the study period 
compared to males (Table 5 & Figure 2).  
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Effect of socioeconomic status on survival. After simultaneously adjusting for gender, age 
group, race, stage, health insurance type, marital status, tumor histology and geographical 
regions, lung cancer patients of  low SES were 22.3 % more likely (HR 1.22, 95%CI  1.16-1.29, 
p<0.001) to die from lung cancer over study period compared to those of  higher SES (reference 
group). There was a clear gradient effect of SES on survival as patients of the middle SES had a 
15.4 percent greater adjusted risk (HR 1.15, 95% CI 1.09-1.22, P<0.001) compared to SES. 
Effect of insurance on survival. Uninsured patients (HR 1.20, 95%CI 1.08-1.34, P<0.001) 
and those with Medicaid (HR 1.13, 95%CI 1.01-1.28, p<0.036) were at higher risk of death 
compared to those with Private insurance or Medicare before (Figure 3) and after (Table 5) 
adjusting for other factors. 
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Effect of histology on survival. Surprisingly, patients with ADK of the lung (HR 0.91, 
95%CI 0.86-0.97, p= 0.003) had better survival compared to SCC after multivariate adjustment. 
As expected, patients with SCLC were 28.1 %  more likely to die (HR 1.28, 95%CI  1.20-1.37, p 
<0.001) compared to those with  SCC after adjusting for gender, age group, race, stage, health 
insurance type, marital status, geographical regions, and SES. 
Effect of marriage on survival. Single patients had a higher risk of death compared to 
married patients (HR 1.20, 95%CI 1.13-1.27, p< 0.001) after simultaneously adjusting for all 
other factors. 
Effect of age on survival. Increasing age at diagnosis showed a clear increase in risk of death 
from lung cancer. Patients less than 45 years old demonstrated the least risk of death. Patients 
more than 75 years old were at highest risk of death (HR 2.63, 95% CI 2.17-3.18, p<0.001 
compared to the reference) (Table 5).  
Effect of stage on survival. Stage at diagnosis proved to be the single most important factor 
in our model. Prior to adjusting for other factors (Figure 4) there was a clear separation of 
survival curves based on stage of lung cancer. This advantage was maintained after 
simultaneously adjusting for adjusting for all other factors. Those with distant disease were 3.65 
times (HR 3.65, 95%CI 3.42-3.89, and p < 0.001) more likely to die over time compared to those 
with localized lung cancer. 
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Hypotheses Testing  
Hypothesis 1. Univariately, there was no difference in survival between Northwestern 
Nevada (reference group) and Southern Nevada (HR 1.01, 95%CI 0.97-1.06, p =0.63) (Table 5). 
However, after multivariate adjustment for age group, gender, stage, health insurance type, 
marital status, SES, tumor histology and race/ethnicity, Southern Nevada Lung cancer patients 
had 8.5 percent higher risk of dying compared to Northwestern Nevada (Table 5). Thus, the null 
hypothesis was rejected. 
Hypothesis 2. There was no difference in receipt of chemotherapy for Blacks with distant 
lung cancer compared to Whites (chi square 0.02, p=0.902) (Table 6). Non significance persisted 
after logistic regression was performed adjusting for sex, age, region, payer, marital status, 
morphology and poverty level (OR 1.11, 95% CI 0.80-1.54, p< 0.524). Thus, the null hypothesis 
could not be rejected. 
 
 
 
 
Table 6 
Chi Square Hypothesis Test for Chemotherapy Treatment for Advanced Lung Cancer,
 Whites vs. Blacks
Yes No
Race Whites 1135 (45.7%) 1350 (54.3%) 2485
Blacks 80 (45.2%) 97 (54.8%) 177
1215 1447 2662
Chemotherapy
Total
Total
Notes:  Pearson’s   Chi square test is 0.015, p =0.902, n= 2662
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Hypothesis 3. There was no significant difference in receipt of surgery in patients with 
localized NSCLC of the lung from Rural Nevada compared to Urban Nevada (Southern Nevada 
and Northwestern combined) with  chi square of 0.59, p=0.442 (Table 7) and logistic regression 
(OR 1.14, 95% CI 0.80-1.62, p=0.467) adjusting for sex, race, age, poverty level, payer, and 
marital status.  
 
Hypothesis 4. Lung cancer patients of low SES were more likely to die from lung cancer 
over the study period compared to those of higher SES (Univariate HR 1.28, 95%CI 1.22-1.36, 
p<0.001: Multivariate HR 1.22, 95%CI 1.16-1.29 p<0.001). (Table 5). The null hypothesis was 
rejected. 
Hypothesis 5. After reclassifying lung cancer into two broad groups of SCLC versus 
NSCLC. Patients with SCLC were at higher risk of death overtime compared to those with 
NSCLC, before and after adjusting for other factors (Univariate HR 1.43, 95%CI 1.35-1.50, 
p<0.001: Multivariate HR 1.26, 95%CI 1.20-1.33, p<0.001) (Table 8). The null hypothesis was 
therefore rejected. 
Table 7
Urban vs. Rural Nevada
No
Region Rural 65 (43%) 151
†Urban 744 (39.8%) 1867
809 2018
†Urban= Southern  and Northwestern Nevada Combined
86 (57%)
1123 (60.2%)
Total 1209
Notes : Pearson's Chi Square Value is 0.590, p=0.442, n=2018
Chi Square Hypothesis Test for Likelihood of Receiving Surgery for a Localized NSCLC
Surgical treatment
Total
Yes
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Sub Analysis 
Further analysis of hypothesis 3 was performed with the Chi square test (Table 9), a 
difference was detected in receipt of surgical treatment by patients with localized NSCLC 
between Southern Nevada and Northwestern Nevada. Logistic regression indicated that Southern 
Nevada patients with localized NSCLC were 32 % less likely to receive surgical treatment 
compared to similar patients in Northwestern Nevada adjusting for age, poverty level, sex, race, 
gender, marital status and insurance status (OR 0.68, 95% CI 0.55-0.85, p< 0.001). 
 
  
Table 8
HR LLCI  ULCI P value* HR LLCI ULCI P value*
Histology <0.001 <0.001
ⱡ NSCLC 1.00 1.00
SCLC 1.43 1.35 1.50 <0.001 1.26 1.20 1.33 <0.001
Unknown 2.63 2.46 2.81 <0.001 2.10 1.95 2.26 <0.001
Notes: Abbreviations: NSCLC, Non Small Cell Lung Cancer which includes   ADK, SCC, and Others.
 SCLC, Small Cell Lung Cancer; HR; Hazard Ratio; LLCI, Lower Limit of 95% Confidence Interval of HR;
 ULCI, Upper  Limit  of 95%  Confidence Interval of HR ; * p value, significant at p<0.05.
†multivariate analysis adjusting for †multivariate analysis adjusting for age, sex, race, region, SES, marital status, stage and insurance 
Univariate (N=12962) †Multivariate (N=12962)
Univariate and Multivariate  Cox Regression Hypothesis  Test of NSCLC  vs. SCLC Survival
Table 9
Northwestern vs. Southern Nevada
Yes No
Northwestern 370 (67%) 182 (33%) 552
Southern 753 (57.3%) 562 (42.7%) 1315
1123 744 1867
Notes : Pearson's Chi Square Value is 15.695, p<0.001, n=1867
 Chi Square Test for Likelihood of Receiving Surgery for Localized NSCLC
Region
Total
Surgical treatment
Total
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Chapter 4 
Discussion 
This study demonstrated that lung cancer is indeed a very deadly cancer, as 82 % of the 
patients were dead by the end of the fifth year of follow-up.  This corresponds to a survival rate of 
16 % after 5 years. Lung cancer survival rate, therefore, contrasts sharply with other cancers such 
as breast and colorectal cancer with 5-year survival rates of 89 % and 65 % respectively (SEER 
Cancer Stat Fact Sheets, 2014). In this study, Nevada lung cancer patients demonstrated 
comparable observed age standardized 5-year survival with patients residing in the SEER region. 
To the best of the author’s knowledge, this was the first time lung cancer survival direct 
comparison had been documented between Nevada and SEER. Studies had been conducted to 
evaluate lung cancer survival disparities (Forrest et al., 2013; Mulligan et al., 2006; Niu et al., 
2013) although none of these studies were specific to Nevada.  Some studies showed overall 
poorer survival for African Americans and other minorities compared to Whites (Gadgeel et al., 
2001; Schwartz & Swanson, 1997). In this study, although Blacks had lower 5-year unadjusted 
lung cancer survival rate, both univariate and multivariate Cox analysis failed to show any 
statistically significant difference between Blacks and Whites. This findings matched that of 
Mulligan et al.( 2006) where no  racioethnic differences in survival were observed under equal 
access to healthcare. That study had suggested that inequality in medical care access could have 
been responsible for a large proportion of racioethnic differences in lung cancer survival.  The 
reason for absence of lung cancer survival disparity between Blacks and Whites in Nevada is 
likely complex and multifactorial. As demonstrated in the Mulligan study, it might be a reflection 
of similar healthcare access in White and Black lung cancer patients in Nevada.  Unlike other 
cancers, due to the fatality of lung cancer, the nature of the disparities may be different. The usual 
prognostics factors associated with other cancers may be attenuated here. It is also plausible, that 
some unaccounted confounders affected the findings despite adequacy of study design and size. 
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More studies are warranted in this area to fully explain lung cancer (or lack thereof) disparity in 
Nevada. Native Americans had significantly lower overall survival rates compared to Whites. 
This was in keeping with previous findings (Lanier, Day, Kelly, & Provost, 2008.; Plescia, 
Henley, Pate, Underwood, & Rhodes, 2014). This result confirms that Nevada Native American 
patients with lung cancer, like their counterparts across United States, are experiencing more 
mortality, likely due to disparities. However, it should be put in proper context during 
interpretation. The small number of Native American cancer patients means one person could 
easily influence the result. 
As with other studies such as that by Tannenbaum et al., (2014), this study suggested that 
the Hispanics and Asians/PFI had better lung cancer survival rates compared to Whites. However, 
there have been questions raised over the accuracy of these findings due to inherent death linkage 
problems for foreign-born populations (Pinheiro , Morris , Liu  & Bungum , 2014).  
 Females did better than their male counterparts across all racial/ ethnicity classes. This 
was in keeping with previous study findings that showed women have greater survival rates 
regardless of stage, histology, treatment modality or smoking status, even after adjusting for 
gender-specific life expectancy (Fu, Kau, Severson, & Kalemkerian, 2005; Thomas, Doyle, & 
Edelman, 2005). This study was not designed to tease out the reason for this difference. It may 
also be related to the fact that more men were smokers. Nonsmoking status predicts better 
survival and may possibly predict better response to therapy (Sun, Schiller, & Gazdar, 2007).  
The etiology behind these observations is theorized to be related to genetic and molecular 
differences (Berardi et al., 2009). Better survival in older women may be related to higher 
prevalence of co-morbidities among men of the same age (Fu et al., 2005). 
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There have been conflicting views in terms of survival between SCC and ADK (Gail et 
al., 1984; L. cancer study Group, 1987). Lung cancer study group found that lung cancer 
recurrences are histopathologically dependent in Stage I NSCLC, with higher rates occurring 
among patients with non SCC. In contrary, this study found that patients with ADK of the lung 
had better survival compared to SCC after multivariate adjustment. As expected, the study 
showed that patients with SCLC were at higher risk of dying compared with SCC.  
This study was able to show significant survival difference between Southern Nevada and 
Northwestern Nevada. This was in keeping with regional disparities noted for other cancers 
described previously (Pinheiro et al., 2012). Although the reason for this regional disparity is not 
clear, it may be related to fewer surgeries being done on localized NSCLC in Southern Nevada. 
The study found that localized NSCLC patients in Southern Nevada were less likely to receive 
surgical treatment compared to similar patients in Northwestern Nevada. Surgery has been shown 
to be the single most important treatment and best chance for cure in localized NSCLC. If this 
result is true and does not correspond to a data artifact, such as a disproportionate lack of 
completeness in recording of treatments of   lung cancer cases by NCCR for Southern Nevada, 
then this is a very important finding for lung cancer disparities in the State. 
 Stage at diagnosis was proven to be the strongest factor affecting lung cancer survival in 
this study. Early diagnosis increases the chances of successful curative surgical treatment. Those 
with distant disease were three and half times more likely to die over period of study after 
simultaneously adjusting for all other factors. Blacks and other racial groups were more likely to 
present late.  
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Inequalities in access to and receipt of quality health care had been reported as a possible 
determinant of lung cancer survival disparities. This study found that uninsured and Medicaid 
patients were at higher risk of death compared to patients with Private insurance or Medicare 
after adjusting for other factors. This was expected as previous studies had reported similar 
findings (Niu et al., 2013). Forrest et al., (2013) looked at SES as a determinant of lung cancer 
survival disparity amongst race/ethnicity groups. They found that patients with lung cancer living 
in more socioeconomically deprived circumstances are less likely to receive any type of 
treatment, surgery, or chemotherapy. Like the Forrest study, this study found that lung cancer 
patients of low SES were at higher risk of death compared to higher and middle SES. This could 
be due to lack of receipt of treatment or lack of access to health care.  
This study also found that married patients with lung cancer had better 5 year survival. 
Marital status has been cited as an important determinant of lung cancer survival outcomes (Jatoi 
et al., 2007; Saito-Nakaya et al., 2008). The positive effects of marriage on lung cancer survival 
have been linked to good social networks, which in turn influence  positively neuroendocrine or 
neuroimmune pathways, health behaviours, access to health care systems and assistance with 
navigating its complexities, the likelihood of receiving vigorous and aggressive, and active cancer 
treatment (Pinquart & Duberstein, 2010).  
Age at diagnosis is also an important predictor of survival for patients with lung cancer 
survival (Howlader N, et al., 2014). This study showed increasing risk of death with aging. Aging 
is generally associated with a decrease in many bodily functions. Consequently elderly patients 
do not have as much physical reserve to combat a serious illness such as cancers as do younger 
people. In this study, all racial minorities had a higher proportion of their population presenting at 
younger age compared to Whites. 
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Strengths 
This study provides an examination of survival disparities among individuals with lung 
cancer for the first time in the state of Nevada. The NCCR data provided a large study population 
with fairly representative proportions of race and ethnic groups allowing for the study of lung 
cancer survival disparities. Matching vital status with SSDI improved accuracy of the assessment 
through complete capture of deaths.  
Limitations 
The quality (completeness) of the data on key variables such as stage of diagnosis and 
histology for which many cancers have an unspecified morphology or stage could have 
influenced the results of this study. The quality of treatment data in cancer registries has not been 
thoroughly assessed across the United States(Bray & Parkin, 2009; Cress et al., 2003; Inwald, 
Klinkhammer-Schalke, Koller, & Ortmann, 2014; Parkin & Bray, 2009; Sinclair et al., 2012; 
Smith-Gagen, Cress, Drake, Felter, & Beaumont, 2005). Also, SES of the study population was 
based on proportion of population under poverty level. This is an ecological measure, which 
might be subject to some degree of ecological fallacy. 
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Chapter 5 
Conclusion 
This study provides much needed baseline lung cancer survival data for Nevada. Lung 
cancer is a very fatal cancer. Nevada's survival rate is comparable to SEER regions. All variables 
of interest contributed significantly to patients’ survival even after simultaneously adjusting for 
other variables. There was no lung cancer survival disparity between Blacks and Whites after 
adjustment for other confounders. The better survival profile of Hispanics and Asian/PFI should 
be interpreted with caution. There is survival disparity across regions, and this may be explained 
in part by lower receipt of surgery at early stage when surgery could impact survival. This finding 
in particular needs to be further studied in order to determine the true cause of regional and racial 
lung cancer disparities in Nevada. 
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